Squarepoint’s Jade Biosciences JBIO Stock Holding History

Squarepoint’s Portfolio JBIO Stock Details JBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.21M	Buy	54,456 +9,806	+22%	+$205K	﹤0.01%	2757
2026 Q1	$627K	Buy	+44,650	New	+$647K	﹤0.01%	3157
2025 Q1	–	Sell	-559	Closed	-$51.8K	–	4564
2024 Q4	$51.8K	Buy	+559	New	+$48.2K	﹤0.01%	4838
2024 Q3	–	Sell	-1,631	Closed	-$94.8K	–	4101
2024 Q2	$94.8K	Buy	+1,631	New	+$1.08M	﹤0.01%	3813
2023 Q4	–	Sell	-504	Closed	-$239K	–	3999
2023 Q3	$239K	Buy	+504	New	+$273K	﹤0.01%	3304
2022 Q1	–	Sell	-370	Closed	-$153K	–	2809
2021 Q4	$153K	Buy	+370	New	+$187K	﹤0.01%	2805
2021 Q3	–	Sell	-257	Closed	-$205K	–	2897
2021 Q2	$205K	Buy	+257	New	+$205K	﹤0.01%	2811

Other funds holding JBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Squarepoint's JBIO Position: Q2 2026 in Review

Squarepoint increased its Jade Biosciences (JBIO) stake by 22% in Q2 2026, buying an estimated $205K and bringing the position to 54,456 shares worth $1.21M. The position accounts for ﹤0.01% of the portfolio, ranked #2757.

Squarepoint first reported a position in JBIO in Q2 2021 and has held it in 7 quarters since. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

Squarepoint held 54,456 shares of Jade Biosciences worth $1.21M as of Q2 2026.
Squarepoint bought 9,806 Jade Biosciences shares in Q2 2026, an estimated $205K.
Jade Biosciences made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2757 holding.
Squarepoint first reported a position in Jade Biosciences in Q2 2021 and has held it in 7 quarters since.
154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.